GHRP-6

GHRP-6 (growth hormone–releasing peptide-6) is another member of the early growth hormone secretagogue family. Like GHRP-2, it was explored for its ability to stimulate endogenous GH release, and it has been widely referenced in experimental and performance-adjacent discussions.

Today, GHRP-6 is more of a legacy agent, with much attention shifting toward other approaches to the GH axis. Its regulatory standing and how it is marketed or used can differ substantially across regions.

GHRP-6 is designed to activate the growth hormone secretagogue receptor and is sometimes described as having prominent ghrelin-like properties. High-level mechanistic themes include:

• Increasing pulsatile GH secretion from the pituitary
• Influencing appetite and hunger signals, often more noticeably than some newer secretagogues
• Interacting with other hormonal systems in ways that are incompletely characterized

These effects have made GHRP-6 a subject of interest in both research and informal settings, but they also raise questions about metabolic and endocrine trade-offs.

As with GHRP-2, GHRP-6 is generally not a mainstream, labeled therapy for growth hormone–related conditions in contemporary practice. It is more likely to appear in historical studies, niche protocols, or unregulated markets.

For individuals with GH-axis concerns, clinicians today often look first to better-characterized diagnostic frameworks and therapies. Any consideration of GHRP-6 in this landscape should be anchored in local regulations and a clear understanding that much published use lies outside standard-of-care pathways.

GHRP-6 is listed explicitly on the WADA Prohibited List under S2.2.4, "Growth hormone releasing factors," among the GHRPs — alexamorelin, examorelin (hexarelin), GHRP-1 through GHRP-6. The UCI's anti-doping tribunal has described it in a published decision as "a Prohibited Substance listed under class S2.2 (Peptide hormones and their releasing factors)" (UCI statement, December 2021). It is a non-Specified Substance, so the default first-offence sanction is four years.

GHRP-6 has an unusual analytical profile among the GH-releasing peptides: it is mostly excreted unchanged. In a controlled nasal-administration study, the parent compound was still detectable in urine 23 hours after a dose, while its metabolites cleared within about 12 hours — the reverse of the pattern for ipamorelin and hexarelin, where free-acid metabolites outlast the parent (Semenistaya et al., Drug Test Anal 2015). Testing therefore targets GHRP-6 itself.

Documented sanctions:

• Luis Ricardo Villalobos Hernández (road cycling), four years. The UCI Anti-Doping Tribunal found GHRP-6 in a sample from the Mexican rider, collected in 2019 while he was with the US Continental team Aevolo; the finding was announced in December 2021, after he had already moved to the WorldTour (UCI statement).

• Raimondas Rumšas Jr. (road cycling), four years. The 23-year-old Lithuanian tested positive for GHRP-6 in an out-of-competition test on 4 September 2017; the ban was announced on 24 January 2018 and ran to 21 October 2022 (VeloNews, 24 January 2018).

• Vahe Aivazian (masters cycling), four years. A USADA investigation established possession and use of ten prohibited substances — "Testosterone, Nandrolone, Dehydroepiandrosterone (DHEA), Somatropin (hGH), Ipamorelin, GHRP-6, CJC-1295, IGF-1, Human chorionic gonadotropin (hCG), Anastrozole." He signed an acceptance of sanction the day before his arbitration hearing; ineligibility began 7 April 2021 (USADA announcement).

The Aivazian case is the pattern most gray-market GHRP-6 use resembles: not a single flagged analyte, but a stack of GH-axis peptides bought together and documented through an investigation rather than a positive test.

Reported effects have included increased appetite, flushing, local injection-site reactions, headache, and nonspecific fatigue. Some reports describe changes in prolactin, cortisol, or other endocrine markers, reflecting a broader physiologic footprint than more selective agents.

As with any intervention that touches the GH/IGF axis, long-term safety questions include potential impacts on glucose metabolism, soft-tissue growth, and underlying neoplastic risk. These considerations highlight the importance of clinician oversight and careful patient selection.

GHRP-6 is a first-generation secretagogue known for stimulating both GH and significant hunger via ghrelin receptors.

This information summarizes commonly discussed research practices. Due to the intense hunger side effect, it is sometimes used specifically for appetite stimulation.

GHRP-6 generally appears as a lyophilized powder for reconstitution. It is a six-residue peptide, His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂, with no structural homology to GHRH — which is why it acts at a different receptor and why the two can be combined (Bowers et al., J Clin Endocrinol Metab 1990).

That combination is the standard way it is presented, usually alongside a GHRH analog such as modified GRF 1-29 or sermorelin. The basis is the original 1990 finding that submaximal GHRP-6 doses of 0.1 and 0.3 µg/kg given with 1 µg/kg GHRH stimulated GH release synergistically, implying the two peptides act through independent systems. Class reviews add that GHRP-6 retains its effect after intravenous, subcutaneous, intranasal and even oral administration, and is only partially blunted by glucose, free fatty acids and glucocorticoids — influences that nearly abolish the response to GHRH alone (Ghigo et al., Eur J Endocrinol 1997). No study has tested the specific blends sold commercially.

Published work on GHRP-6 has focused on its ability to stimulate GH and related endocrine responses, sometimes in comparison with other secretagogues. Some studies and reports have examined effects on appetite, body composition, or recovery markers.

The overall evidence base is mixed and relatively specialized, and newer therapies have taken center stage for many clinical questions. As with other peptides on this site, interpretation of GHRP-6 data benefits from a close look at study quality and regulatory context.

For deeper dives on this peptide, see:

• GHRP-6 benefits and areas of interest
• GHRP-6 side effects and safety context
• GHRP-6 dosing concepts (educational)
• GHRP-6 research and evidence overview

How much growth hormone does GHRP-6 actually release? A lot, dose-dependently. In 18 normal men given intravenous boluses, mean peak serum GH was 1.2 µg/L on placebo and 7.6, 16.5 and 68.7 µg/L at 0.1, 0.3 and 1.0 µg/kg respectively — roughly a 57-fold rise over placebo at the top dose (Bowers et al., J Clin Endocrinol Metab 1990).

Does it raise prolactin and cortisol? Only at the top of that range. In the same study, prolactin and cortisol rose about two-fold above baseline only at 1.0 µg/kg — not at 0.1 or 0.3 — and LH and TSH did not change in the first hour. No adverse clinical effects or laboratory abnormalities were observed in response to GHRP-6 at any dose.

Why is GHRP-6 historically important? Because it should not have worked. A synthetic hexapeptide with no structural homology to GHRH, releasing GH potently through its own receptor, implied that a natural ligand for that receptor existed. The authors closed by proposing exactly that — "a new physiological system in need of further characterization." In 1999 the missing ligand was purified from stomach and named ghrelin (Kojima et al., Nature 1999).

Is the hunger effect real? The mechanism is: GHRP-6 agonises the ghrelin receptor, and ghrelin drives food intake. The controlled human measurement, though, was made with GHRP-2, where a subcutaneous infusion increased buffet-meal intake by 35.9 ± 10.9% versus saline (Laferrère et al., J Clin Endocrinol Metab 2005). Expect the effect from the receptor; do not expect a published number attached to GHRP-6 itself.

Does GHRP-6 cause flushing? This is a persistent misattribution. In the 1990 study, mild facial flushing lasting one to three minutes occurred in 16 of 18 men — in response to GHRH, not to GHRP-6. Flushing is a GHRH-family effect; the GHRP arm did not produce it.

Is it banned in sport? Yes, prohibited at all times under WADA section S2. Unlike its siblings, GHRP-6 is excreted mostly unchanged and has been detected in urine 23 hours after administration, with metabolites detectable for about 12 (Semenistaya et al., Drug Test Anal 2015).